Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Group 1 - The article discusses the performance and outlook of Pfizer Inc. (PFE), indicating a bullish sentiment towards the stock based on its competitive advantages and defensibility in the market [1] - The analysis emphasizes a focus on high-quality companies that can outperform the market over the long term, particularly in the European and North American markets [1] Group 2 - The author has a beneficial long position in Novo Nordisk (NVO) shares, indicating a personal investment interest in the company [2] - The article expresses the author's own opinions and does not involve compensation from any company mentioned, ensuring an independent perspective [2]